Antigen News and Research

RSS

PharmAthene reports progress in lyophilized rPA anthrax vaccine development program

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it continues to make solid progress in its lyophilized recombinant Protective Antigen (rPA) anthrax vaccine development program. The Company has recently demonstrated that its lyophilized rPA vaccine candidate is structurally stable and potent at various temperatures up to and including 70 degrees centigrade.

9 Jul 2010

Trigger that induces B cells to produce early, effective antibody response discovered

Researchers at National Jewish Health have discovered a trigger that induces B cells to produce effective and long-lived antibodies early in the immune response. They found that a molecule that binds toll-like receptors doubles the early antibody response to an antigen, and shifts it to a more effective, IgG form.

7 Jul 2010

Further analysis on Bcl11b gene and T-cell behaviouur from Caltech Biologists

When does a cell decide its particular identity? According to biologists at the California Institute of Technology (Caltech), in the case of T cells-immune system cells that help destroy invading pathogens-the answer is when the cells begin expressing a particular gene called Bcl11b.

3 Jul 2010

Neogenix Oncology files patent application with USPTO for 16C3 antigen

Neogenix Oncology announced today that the company has filed a patent application with the U.S. Patent and Trade Office (USPTO) for the 16C3 antigen. The Company believes that this antigen is tumor specific for pancreatic and colorectal tumors; and, based on preliminary clinical data, may also have diagnostic utility as a biomarker for these cancers.

3 Jul 2010

Researchers develop first model of hormone-induced human prostate cancer initiation and progression

Progress toward understanding the role of sex hormones in the growth of prostate cancer—the most common cancer in U.S. men—has been hindered by the lack of a suitable laboratory research model. Now researchers say they have developed the first model of hormone-induced human prostate cancer initiation and progression.

2 Jul 2010

Compugen's CGEN-15001 recombinant fusion protein abolishes spontaneous relapses in animal model of MS

Compugen Ltd. announced today that administration of CGEN-15001 in an animal model of multiple sclerosis (MS) has been shown to completely abolish spontaneous relapses. In addition, administration of this novel molecule prior to disease onset demonstrated a pronounced delay of disease onset and a significant decrease in disease symptoms.

2 Jul 2010

Mice study may provide new insight on human pregnancies

The concept of pregnancy makes no sense-at least not from an immunological point of view. After all, a fetus, carrying half of its father's genome, is biologically distinct from its mother. The fetus is thus made of cells and tissues that are very much not "self"-and not-self is precisely what the immune system is meant to search out and destroy.

2 Jul 2010

InNexus develops IXS312 small protein fragment as topical therapy for AMD, diabetic retinal dysplasia

InNexus Biotechnology Inc., a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced that it has developed IXS312(VEGF), an antibody fragment with activity against the growth factor VEGF for planned use in ocular treatments.

30 Jun 2010

Claros point-of-care system for PSA receives European CE Mark approval

Claros Diagnostics, a developer of novel point-of-care in vitro diagnostic systems, today announced the CE Mark approval for its rapid quantitative point-of-care diagnostic platform, which can now be used for prostate specific antigen (PSA) testing throughout the European Union. The approved system consists of a small portable analyzer and credit card-sized disposable.

29 Jun 2010

BIND Biosciences announces $12.4 million Series C-1 financing

BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company developing best in class therapeutics based on its proprietary targeted nanotechnology platform, announced today that it has secured a $12.4 Million Series C-1 financing. This financing included all of BIND's current investors (including Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension and DHK Investments) as well as a new venture investor, Endeavour Vision, and private investors.

29 Jun 2010

LEAPS vaccine technology generates dendritic cells to stimulate immune system to fight viral illnesses

CEL-SCI Corporation and researchers at the Northeastern Ohio Universities Colleges of Medicine and Pharmacy (NEOUCOM) jointly announced today that a LEAPS-based vaccine (Ligand Epitope Antigen Presentation System) study has demonstrated the technology's potential using dendritic cells to stimulate the immune system to fight viral illnesses and other diseases.

29 Jun 2010

Tolerx presents preclinical data on TRX518 anti-GITR immunotherapy for cancer

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, presented results from preclinical studies with TRX518, an early-stage agent Tolerx is developing as a treatment for cancer. TRX518 is a monoclonal antibody to glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed to enhance the immune system's ability to attack tumors by activating and rendering T effector cells resistant to T regulatory cell suppression.

28 Jun 2010

IDRI signs Research Collaboration Agreement with PATH

Two global health non-profit organizations headquartered in Seattle, Washington, the Infectious Disease Research Institute and PATH, have entered into a Research Collaboration Agreement to evaluate novel adjuvants for their ability to enhance the immune response of pandemic influenza vaccines in development. The collaboration supports the goal of PATH's influenza vaccine project to advance the development of promising new influenza vaccines focusing on novel technologies that can be accessible, affordable, and available to people in low-resource countries in a global outbreak.

25 Jun 2010

Phadia's four new EliA autoimmune antibody assays receive FDA clearance

Today Phadia announced that it has received FDA 510 (K) clearance for four new EliA autoimmune antibody assays. These new assays will provide physicians with additional tools needed to aid in the diagnosis of Antiphospholipid Syndrome. The newly available EliA assays, anti-cardiolipin (aCL) IgG/IgM and anti-B2-glycoprotein 1 (anti-B2-GP1) IgG/IgM, have proven to be essential, sensitive, and specific markers to aid in the diagnosis of APS.

25 Jun 2010

Sanofi-aventis' Phase I clinical trial with SAR650984 triggers $1M milestone payment to ImmunoGen

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced that sanofi-aventis has initiated a Phase I clinical trial with SAR650984, an investigational antibody that targets cancer cells expressing the CD38 protein antigen. This event triggers a $1 million milestone payment to ImmunoGen.

25 Jun 2010

Patent application for tumor specific NPC-1C Antigen filed by Neogenix Oncology

Neogenix Oncology announced today that it has filed a patent application with the US Patent and Trade Office for the NPC-1C antigen. This antigen appears to be tumor specific for pancreatic and colorectal tumors.

24 Jun 2010

UCSD researchers awarded $2.5M CIRM grant to explore stem cells

A pair of University of California San Diego researchers - Martin Marsala, a specialist in spinal cord trauma and disorders, and Yang Xu, an immunologist - have been awarded more than $2.5 million in new grants from the California Institute for Regenerative Medicine.

24 Jun 2010

Aphios awarded US patent for process to formulate polymeric microspheres, nanospheres

Aphios Corporation today announced that it was awarded United States Patent No. 7,708,915 B2 for "Polymer Microspheres/Nanospheres and Encapsulating Therapeutic Proteins Therein," granted May 04, 2010. This invention is an improved process to formulate polymeric microspheres and nanospheres, and encapsulate therapeutic proteins or other useful substances, and a polymer microspheres/nanospheres apparatus.

24 Jun 2010

Cedars-Sinai researchers awarded $1.47M grant to study stem cell immune rejection response

A team of Cedars-Sinai Regenerative Medicine Institute researchers led by Terrence Town, Ph.D. has been awarded a three-year, $1.47 million grant from the California Institute for Regenerative Medicine to fund research into mechanisms for how human immune systems reject or accept transplanted brain stem cells.

24 Jun 2010

SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the peer-reviewed journal Molecular Therapy has published a paper entitled "Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques." The paper, co-authored by researchers from Merck, University of Pennsylvania School of Medicine, and Inovio Pharmaceuticals, notes that significant advances in the design, formulation, and delivery of DNA plasmid-based vaccines have dramatically increased their ability to induce antigen-specific immune responses.

22 Jun 2010

Antigen News and Research

PharmAthene reports progress in lyophilized rPA anthrax vaccine development program

Trigger that induces B cells to produce early, effective antibody response discovered

Further analysis on Bcl11b gene and T-cell behaviouur from Caltech Biologists

Neogenix Oncology files patent application with USPTO for 16C3 antigen

Researchers develop first model of hormone-induced human prostate cancer initiation and progression

Compugen's CGEN-15001 recombinant fusion protein abolishes spontaneous relapses in animal model of MS

Mice study may provide new insight on human pregnancies

InNexus develops IXS312 small protein fragment as topical therapy for AMD, diabetic retinal dysplasia

Claros point-of-care system for PSA receives European CE Mark approval

BIND Biosciences announces $12.4 million Series C-1 financing

LEAPS vaccine technology generates dendritic cells to stimulate immune system to fight viral illnesses

Tolerx presents preclinical data on TRX518 anti-GITR immunotherapy for cancer

IDRI signs Research Collaboration Agreement with PATH

Phadia's four new EliA autoimmune antibody assays receive FDA clearance

Sanofi-aventis' Phase I clinical trial with SAR650984 triggers $1M milestone payment to ImmunoGen

Patent application for tumor specific NPC-1C Antigen filed by Neogenix Oncology

UCSD researchers awarded $2.5M CIRM grant to explore stem cells

Aphios awarded US patent for process to formulate polymeric microspheres, nanospheres

Cedars-Sinai researchers awarded $1.47M grant to study stem cell immune rejection response

SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics